Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1016/j.jdiacomp.2015.04.003. Epub 2015 Apr 11.
Affiliations
- PMID: 25981123
- DOI: 10.1016/j.jdiacomp.2015.04.003
Free article
Randomized Controlled Trial
Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study
Pablo Aschner et al. J Diabetes Complications. 2015 Aug.
Free article
Abstract
Aims: Demonstrate superiority of insulin glargine (±glulisine) strategy versus premixed insulin strategy for percentage of patients reaching HbA1c <7% (<53 mmol/mol) at study end without any documented symptomatic hypoglycemia (bloof glucose [BG] ≤3.1 mmol/L) in type 2 diabetes (T2DM) patients failing oral agents.
Methods: This 24-week, open-label, multinational trial randomized patients to glargine OD or premix OD or BID, continuing metformin ± insulin secretagogue (IS). Second premix injection could be added any time; glulisine could be added with main meal in glargine OD patients with HbA1c ≥7% and fasting blood glucose (FBG) <7 mmol/L at week 12. IS was stopped with any second injection. Insulin titration targeted FBG ≤5.6 mmol/L.
Results: Modified intent-to-treat population comprised 923 patients (glargine, 462; premix, 461). Baseline characteristics were similar (mean T2DM duration: 9 years; HbA1c: 8.7% (72 mmol/mol); FBG: 10.4 mmol/L). Primary endpoint was achieved by 33.2% of glargine (±glulisine) and 31.4% of premix patients. Superiority was not demonstrated, but non-inferiority was (pre-specified margin: 25% of premix rate). More patients using premix achieved target (52.6% vs. 43.2%, p=0.005); symptomatic hypoglycemia was less with glargine (1.17 vs. 2.93 events/patient-year).
Conclusions: Glargine (±glulisine) and premix strategies resulted in similar percentages of well-controlled patients without hypoglycemia, with more patients achieving target HbA1c with premix whereas overall symptomatic hypoglycemia was less with glargine.
Keywords: GALAPAGOS; Hypoglycemia; Insulin glargine; Premixed insulin; Type 2 diabetes.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
- Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Rosenstock J, Guerci B, Hanefeld M, Gentile S, Aronson R, Tinahones FJ, Roy-Duval C, Souhami E, Wardecki M, Ye J, Perfetti R, Heller S; GetGoal Duo-2 Trial Investigators. Rosenstock J, et al. Diabetes Care. 2016 Aug;39(8):1318-28. doi: 10.2337/dc16-0014. Epub 2016 May 23. Diabetes Care. 2016. PMID: 27222510 Clinical Trial. - Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I, Pérez Manghi F, García-Hernández P, Norwood P, Lehmann L, Tarp-Johansen MJ, Buse JB; DUAL V Investigators. Lingvay I, et al. JAMA. 2016 Mar 1;315(9):898-907. doi: 10.1001/jama.2016.1252. JAMA. 2016. PMID: 26934259 Clinical Trial. - Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Giugliano D, Chiodini P, Maiorino MI, Bellastella G, Esposito K. Giugliano D, et al. Endocrine. 2016 Mar;51(3):417-28. doi: 10.1007/s12020-015-0718-3. Epub 2015 Aug 18. Endocrine. 2016. PMID: 26281001 Review. - Consensus on Initiation and Intensification of Premix Insulin in Type 2 Diabetes Management.
Mohan V, Kalra S, Kesavadev J, Singh AK, Kumar A, Unnikrishnan AG, Chawla R, Mukherjee JJ, Sahay RK, Kumar JS, Bhoraskar A, Asirvatham AJ, Panda JK, Zargar AH, Das AK. Mohan V, et al. J Assoc Physicians India. 2017 Apr;65(4):59-73. J Assoc Physicians India. 2017. PMID: 28527166
Cited by
- 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association.
Moon JS, Kang S, Choi JH, Lee KA, Moon JH, Chon S, Kim DJ, Kim HJ, Seo JA, Kim MK, Lim JH, Song YJ, Yang YS, Kim JH, Lee YB, Noh J, Hur KY, Park JS, Rhee SY, Kim HJ, Kim HM, Ko JH, Kim NH, Kim CH, Ahn J, Oh TJ, Kim SK, Kim J, Han E, Jin SM, Bae J, Jeon E, Kim JM, Kang SM, Park JH, Yun JS, Cha BS, Moon MK, Lee BW. Moon JS, et al. Diabetes Metab J. 2024 Jul;48(4):546-708. doi: 10.4093/dmj.2024.0249. Epub 2024 Jul 26. Diabetes Metab J. 2024. PMID: 39091005 Free PMC article. No abstract available. - Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era.
Shrivastava A, Kesavadev J, Mohan V, Saboo B, Shrestha D, Maheshwari A, Makkar BM, Modi KD, Kumar Das A. Shrivastava A, et al. Curr Diabetes Rev. 2023;19(8):e090123212444. doi: 10.2174/1573399819666230109104300. Curr Diabetes Rev. 2023. PMID: 36624650 Free PMC article. Review. - Twenty Years of Insulin Gla-100: A Systematic Evaluation of Its Efficacy and Safety in Type 2 Diabetes Mellitus.
Sethi B, Unnikrishnan AG, Ayyar V, Jabbar PK, Ganguly KK, Bhandari S, Rastogi A, Mukherjee R, Sundaram V, Asirvatham AR. Sethi B, et al. Diabetes Ther. 2022 Aug;13(8):1409-1481. doi: 10.1007/s13300-022-01284-2. Epub 2022 Jun 30. Diabetes Ther. 2022. PMID: 35768707 Free PMC article. Review. - Efficacy and safety of a basal insulin + 2-3 oral antihyperglycaemic drugs regimen versus a twice-daily premixed insulin + metformin regimen after short-term intensive insulin therapy in individuals with type 2 diabetes: The multicentre, open-label, randomized controlled BEYOND-V trial.
Pan Q, Li Y, Wan H, Wang J, Xu B, Wang G, Jiang C, Liang L, Feng W, Liu J, Wang T, Zhang X, Cui N, Mu Y, Guo L; BEYOND V Study Investigators. Pan Q, et al. Diabetes Obes Metab. 2022 Oct;24(10):1957-1966. doi: 10.1111/dom.14780. Epub 2022 Jun 28. Diabetes Obes Metab. 2022. PMID: 35642463 Free PMC article. Clinical Trial. - 2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association.
Hur KY, Moon MK, Park JS, Kim SK, Lee SH, Yun JS, Baek JH, Noh J, Lee BW, Oh TJ, Chon S, Yang YS, Son JW, Choi JH, Song KH, Kim NH, Kim SY, Kim JW, Rhee SY, Lee YB, Jin SM, Kim JH, Kim CH, Kim DJ, Chun S, Rhee EJ, Kim HM, Kim HJ, Jee D, Kim JH, Choi WS, Lee EY, Yoon KH, Ko SH; Committee of Clinical Practice Guidelines, Korean Diabetes Association. Hur KY, et al. Diabetes Metab J. 2021 Jul;45(4):461-481. doi: 10.4093/dmj.2021.0156. Epub 2021 Jul 30. Diabetes Metab J. 2021. PMID: 34352984 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical